Objective: Endovascular aneurysm repair (EVAR) of abdominal aortic aneurysms (AAAs) has gained widespread use through a solid reputation of safety and effectiveness. However, some issues, such as endoleaks and sac growth over time, still arise as important concerns. Antiplatelet therapy, mandatory as secondary prevention of cardiovascular disease, may play a role in both phenomena by interfering with blood clotting properties and the inflammatory process associated with AAA. We analyzed whether different antiplatelet therapies were independent risk factors for type II endoleak (T2E) persistence and midterm sac growth after EVAR.
Endovascular aneurysm repair (EVAR) has gained widespread use by proving better short-term outcomes than conventional open surgery. In the long term, the main clinical trials have shown a similar performance for both techniques but with a higher rate of reinterventions in the EVAR group.
1,2 A close imaging surveillance is still needed to detect endoleaks and aneurysmal sac expansion, which remains a big concern and can lead to rupture, with devastating results. 3, 4 Type II endoleaks (T2Es) are a frequent finding after EVAR, with incidence ranging from 12.0% 5 to 40.5% 6 during follow-up. Although some of them resolve spontaneously and T2Es seldom lead to long-term sac rupture, they are associated with increased rates of sac growth, reintervention, and open conversion. [7] [8] [9] [10] [11] [12] [13] [14] For all this, T2Es
can threaten the overall benefit-cost ratio of the EVAR technique. 15 In addition, few effective predictors of sac growth have been described in populations diagnosed with T2E, and the few described are primarily related to the endoleak's morphologic characteristics. [16] [17] [18] [19] [20] Some studies suggest that antiplatelet therapy, anticoagulation, and fibrinolysis may play a role in T2E development and sac shrinkage after EVAR. [21] [22] [23] [24] [25] [26] We conducted a study to determine whether the antiplatelet agent associated with patients with a T2E detected in the first post-EVAR control may have an influence on the endoleak's persistence and aneurysmal sac behavior over time.
METHODS
During a 9-year contiguous period (January 2003-December 2011), all patients undergoing a programmed EVAR in two tertiary care institutions from the north of Spain were prospectively enrolled into a clinical database. Demographics, risk factors, comorbidities, pre-EVAR aneurysm diameter, implanted devices, antiplatelet therapy on discharge, and outcomes were registered. The presence of clinical cardiovascular disease was defined as one of the following: coronary episode (stable or unstable angina, ST-segment or non-ST-segment elevation myocardial infarction), cerebrovascular disease (transient ischemic attack or ictus), or peripheral arterial disease (Fontaine IIa or higher).
All patients underwent a contrast-enhanced biphasic tomographic evaluation during the first 7 postoperative days. Those studies were evaluated for the presence of a T2E by an experienced vascular surgeon using the software OsiriX (Pixmeo Sàrl, Geneva, Switzerland). The bidimensional Digital Imaging and Communications in Medicine files were then segmented into a threedimensional (3D) endoleak model for detailed volumetry, using the software Mimics (Materialise NV, Leuven, Belgium). Each endoleak was described by its maximum axial diameter, 3D-rendered volume, number of collateral vessels in contact with the nidus and their diameter, and disposition (cylindrical, semilunar, or circundant).
Patients were followed up for endoleak persistence, mortality, and aneurysmal sac growth over time, stratified by the platelet antiaggregation method prescribed at the moment of discharge. Therapeutic adherence was assessed by the primary care physician and the vascular specialist in the subsequent visits. During follow-up, contrast-enhanced tomography scans were performed at 6 months, 1 year, and yearly thereafter in the presence of a T2E. Twenty-six patients did not fulfill at least 1 year of follow-up (three consecutive enhanced tomographic evaluations) and were excluded from the study. Some patients without sac growth or identifiable endoleaks were put on ultrasound surveillance; contrast-enhanced ultrasound was used discretionally or in preparation for an eventual T2E treatment when needed. An increment of 5 mm over the maximum pre-EVAR axial diameter of the aneurysm was considered the main end point of the study. Because of the study's retrospective nature, the Ethics Committee of each center dismissed both the need of a specific approval for this work and the need of the patient's informed consent.
Statistics. Quantitative variables were described by mean and standard deviation, using median and rank instead if the distribution was not symmetric. When required, normality was assessed using the KolmogorovSmirnov test. Qualitative variables were described using frequencies. For bivariate associations, Student t-test, analysis of variance, Pearson c 2 test, and Freeman-Halton extension of the Fischer exact test were used. 27 A Cox proportional hazards model was built to determine the relationship between sac growth and several potential predictors identified in previous reports: age, maximum aneurysm diameter, diameter of patent collateral vessels, endoleak complexity, and endoleak nidus volume. 10, 17, 19, 20, 28 Other variables with a significant bivariate association in our population were also included in the model. A value of P < .05 was considered significant for all calculations.
RESULTS
In a 9-year period, 367 patients underwent EVAR. Twenty-two patients did not fulfill the first imaging control for diverse reasons (in-hospital mortality, open conversion, or allergy to contrast material) and were subsequently excluded from the T2E incidence workout. Thus, the immediate post-EVAR T2E rate was 31% (113/367). Of those, 87 patients (92% male) with at least 1 year of complete imaging follow-up were included. Mean follow-up lasted 41.5 6 28 months. Mean age was 76.0 6 7 years (youngest, 53 years; oldest, 95 years), and median pre-EVAR aneurysm diameter was 57. Antiplatelet therapy. On discharge, 12 patients (14%) did not receive any antiplatelet agent. Four patients (5%) were prescribed low-molecular-weight heparin and then the oral anticoagulants they were given before EVAR were reintroduced because of chronic atrial fibrillation. Five patients (6%) received multiagent antiplatelet therapy (always aspirin þ clopidogrel) because of previously treated coronary disease. Sixteen patients (18%) were given 75 mg/day of clopidogrel, 23 patients (26%) received 600 mg/day of triflusal, and 27 (31%) Recommendation: The authors suggest that aspirin therapy after endovascular aneurysm repair with type II endoleaks is superior to either no therapy or other antiplatelet or anticoagulation therapies in the resolution of the endoleak. received aspirin. Of those, 24 were given a dose of 100 mg/day, and another 3 were given a dose of 150 mg/ day.
ARTICLE HIGHLIGHTS
Endoleak description. T2Es identified in the first imaging control had a mean nidus axial diameter of 15.3 6 7 mm and a mean 3D-rendered volume of 2.69 6 2.4 mL (rank, 0.22-12.68 mL). Fifty-four of the endoleaks (62%) were in contact with a single identifiable vessel, whereas another 33 (38%) were in contact with two or more collateral vessels (complex endoleaks). The main identifiable vessel was a lumbar artery in 48 subjects (mean caliber, 2.60 6 .8 mm), an inferior mesenteric artery in 30 (mean caliber, 3.16 6 1.6 mm), a hypogastric artery in 7 (mean caliber, 5.11 6 2.0 mm), and a polar renal artery in 2 cases. Nine patients had two simultaneous and independent endoleak niduses (multiple endoleaks), and another six had a single nidus disposed around the endograft in a circundant way.
Outcomes and inferential statistics. Of the initial 87 endoleaks, 51 (59%) persisted on the second imaging control, performed 6 months thereafter. Over time, 32 patients of those with T2E detected on the first computed tomography scan (37%) experienced a 5-mm increase in the abdominal aortic aneurysm (AAA) diameter over the preoperative size. In another 25 patients (29%), the diameter stayed within a 65-mm range, and finally 30 patients (34%) experienced sac shrinkage of >5 mm.
Persistent endoleaks were significantly associated with sac growth >5 mm at end of follow-up (53% vs 14%; c 2 , P < .001). Both in the four-way comparison (Table I) and in the comparisons between the group taking salicylates and the rest of the patients, excluding those who were not prescribed antiplatelet therapy (Table II) , the sac growth risk was significantly lower for the patients receiving salicylates. The free-of-growth survival was also significantly superior for that treatment (log-rank, P ¼ .003; Fig 1) , with a 62% free of 5-mm growth survival for the patients taking salicylates at 4 years vs 28% for the group receiving other therapies (clopidogrel, multiagent antiplatelet therapy, or anticoagulation). In the subgroup with persistent endoleaks (n ¼ 51), salicylates did also behave like a protective factor over sac growth (35% >5-mm growth rate for persistent endoleaks with salicylates vs 72% rate for those receiving other treatments; c 2 , P ¼ .007).
No significant differences between groups with different antiplatelet regimens were found in terms of preoperative conditions, risk factors, or endoleak morphologic characteristics (Tables I and II) . No difference in the mean volume of the T2E nidus was found between the group taking salicylates and the groups receiving other treatments (P ¼ .326; Fig 2) .
Finally, the treatment with salicylates (c 2 , P ¼ .015), the endoleak's nidus volume (Student t-test, P ¼ .003), and the use of an Excluder endograft (c 2 , P ¼ .039) showed a significant bivariate association with sac growth >5 mm at end of follow-up. The proportional hazards Cox model that was built together with other covariates (Table III) had a significant likelihood ratio test (omnibus, P ¼ .006) for the goodness of fit. A complex endoleak and the nidus volume showed up as independent predictors of sac growth, whereas the treatment with salicylates behaved like an independent protector factor (hazard ratio [HR], 0.337; 95% confidence interval [CI], 0.13-0.87; P ¼ .024).
DISCUSSION
Although asymptomatic, the diagnosis of an AAA is considered a coronary disease equivalent and thus should lead to secondary prevention of cardiovascular 30 In our population, triflusal was also used as secondary prevention in 23 patients (26%). Triflusal is a platelet aggregation inhibitor of the salicylate family but not a derivative of acetylsalicylic acid. It has comparable antiplatelet activity to aspirin but with a more favorable safety profile in terms of hemorrhagic events by leaving intact the arachidonic acid metabolic pathway in endothelial cells. 32 The most recent guidelines on aortic aneurysmal disease advise that all patients should be started on antiplatelet therapy at the time of diagnosis. 33 In addition, all patients receiving an aortic endograft should be kept on the best medical treatment, including antiplatelet agents. 33 Although no specific trials have been performed on an AAA population, a meta-analysis suggested that the use of low-dose aspirin is associated with a reduction in major coronary events and stroke, with a 10% overall reduction in total mortality. 34 Several studies have suggested a role for antiplatelet or anticoagulation therapy in aneurysm evolution after EVAR. The results of a study conducted by Bobadilla et al in 2010 and a meta-analysis by Lazarides et al in 2014 concluded that warfarin therapy increases the risk of any kind of endoleak and sac expansion during follow-up. 24, 25 Specifically, this latter study associated anticoagulation with an enhanced risk of persistent T2E over time. The work by Aoki et al published in 2011 also found an association between multiagent antiplatelet therapy and a lack of aneurysm shrinkage 6 months after EVAR, but without relating antiaggregation to T2Es. 35 None of these works included a multivariate approach to adjust for potential confounders. On the other hand, a study by Wild et al (2014) did not find any significant difference in endoleak rates or sac growth 18 months after EVAR for patients taking anticoagulation, receiving antiplatelet therapy, or untreated. 23 No separate analysis for different antiplatelet regimens was performed in this study. Our work attracts attention to the role of salicylate therapy as a protector from sac growth vs other antiplatelet agents, including multiagent therapy and even anticoagulation. Four years after EVAR, 72% of the nonsalicylate group of patients had an aneurysmal sac growth of 5 mm or more vs only 38% of the patients treated with aspirin or triflusal (P ¼ .003). The interpretation of the Cox proportional hazards model shows that the hazard of experiencing significant sac growth is reduced to 66% for each year a patient has been taking salicylates. To our knowledge, this is the first time this fact has been reported. Explaining why this occurs is difficult; there is evidence in animal models that suggests a protective effect of aspirin over aneurysmal growth and rupture, as activated platelets may have a role in the inflammation pathway that triggers AAA development and growth. [36] [37] [38] In humans, some studies have pointed to lower expansion rates and less need of surgical repair for patients with medium-sized abdominal aneurysms and associated aspirin. 22, 39 Determining if the effect on sac growth in the populations with T2E is due to an action over blood clotting properties or over thrombus/ sac behavior could be the object of further investigations. The salicylate group also had a lower rate of 6-month persistence of the T2E (52% vs 68%), although this difference did not reach statistical significance, probably because of the limited sample size. The differences found in mortality should also be interpreted carefully because of the low frequency of those events (n ¼ 13), which prevents any solid conclusion from being drawn. That the endoleak nidus volume was the strongest independent predictor of sac growth over time (HR, 1.22; 95% CI, 1.05-1.42; P ¼ .008) in our sample deserves special attention. Complex endoleaks also acted as an independent predictor (HR, 5.07; 95% CI, 1.62-15.85; P ¼ .005), but the width of the CI somewhat hinders a real application of that predictive capacity. Several previous reports have highlighted the value of T2E volumetry as a predictor of reintervention and sac growth. [18] [19] [20] 28 However, all these studies are based on relatively small samples (ranging from 56 to 72 patients), most of them use planimetric methods for determining the volume of the T2E, and only one embodies a multivariant analysis. [18] [19] [20] 28 The paper by Müller-Wille et al published in 2015 uses a similar approach to ours, both performing volumetry with a dedicated 3D workstation and trying to identify potential predictors by building a multivariate logistic regression model. 20 The results are concordant with ours, highlighting the role of nidus volume and endoleak complexity for predicting aneurysmal sac enlargement over time, although the potential role played by antiplatelet therapy was not taken into account. A further and more detailed analysis of the predictive profile of volumetry in our sample will be conducted. Some of the previous studies have considered the endoleak maximum diameter, measured in axial slices, a potential marker of sac growth. 16, 19, 28 However, criterion issues may arise in determining this diameter in patients with complex endoleak geometries or several coexisting endoleak cavities. Other works do not recommend the use of this parameter as a prognosis marker, and some state that up to 63% of sac growth associated with T2E cannot be predicted by using the diameter alone. 20, 40, 41 Our study has several limitations that should be taken into account. Leaving apart sample size considerations, our imaging protocol did not include the routine performance of delayed-phase acquisitions in the first post-EVAR control. Allegedly, delayed-phase tomography enhances the sensitivity of the test for detecting endoleaks but does not hinder the anatomic analysis and 3D rendering of the ones that have already been detected. The already mentioned study by Müller-Wille et al did not find significant differences in the rendered volume of an endoleak between arterial and delayed (venous) phases. 20 Other studies have been performed using arterial phases alone, and their results do not differ from those of the studies that used delayed-phase acquisitions. 16, 18, 19, 28 Also, no information was available on the role that each collateral vessel played in complex endoleaks or which flow pattern they presented (variable with respiratory movements or Valsalva maneuvers, to-and-fro); as stated before, detailed contrast-enhanced ultrasound was performed in selected cases, usually while preparing for a transarterial treatment approach.
CONCLUSIONS
Secondary prevention of cardiovascular disease using salicylates may condition lower rates of midterm aneurysmal sac growth in patients with a T2E than with other antiplatelet or anticoagulation regimens. Ideally, this result should be confirmed by population-based cohort studies before a solid recommendation of a given therapy can be made. 
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